<DOC>
	<DOCNO>NCT02963350</DOCNO>
	<brief_summary>- To provide access BMN 190 patient CLN2 disease participate clinical trial . - To collect additional information safety tolerability BMN 190 administration patient CLN2 disease .</brief_summary>
	<brief_title>A Multicenter , Multi-national Open-label Program Provide BMN 190 Patients Diagnosed With CLN2 Disease</brief_title>
	<detailed_description />
	<criteria>Diagnosed CLN2 disease confirm deficient TPP1 enzyme activity leukocytes molecular analysis identify 2 know pathogenic mutation . If enzyme analysis perform dried blood spot , diagnosis must confirm molecular test Age â‰¥2 old time inform consent Is willing able provide write , sign informed consent . Or , case patient age 18 ( age define regional law regulation ) , provide write assent ( require ) write informed consent , sign legally authorize representative , nature program explain , prior program assessment . If sexually active , must willing use 2 form acceptable method contraception participate program . If female childbearing potential , must negative pregnancy test Baseline willing additional pregnancy test program . Willing able comply program procedure . Another inherited neurologic disease , e.g. , form CLN seizure unrelated TPPI deficiency/CLN2 disease ( patient febrile seizure may eligible ) . Has receive stem cell , gene therapy , ERT CLN2 disease . Contraindications neurosurgery ( e.g. , congenital heart disease , severe respiratory impairment , clot abnormality ) . Contraindications MRI scan ( e.g. , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) . Episode generalize motor status epilepticus within 4 week first infusion . Presence ventricular abnormality ( hydrocephalus , malformation ) . Presence ventricular shunt . Has know hypersensitivity component BMN 190 . Currently enrol previously enrol clinical study BMN 190 . Use investigational product investigational medical device within 30 day prior Baseline , requirement investigational agent prior completion schedule program assessment . Have travel plan may interfere dose regimen , schedule program visit safety monitoring . Has medical condition extenuate circumstance , opinion physician , might compromise patient 's ability comply protocol require testing procedure compromise patient 's wellbeing , safety , clinical interpretability . Pregnancy time program ; female patient judge physician childbearing potential tested pregnancy . A CLN2 combine motor/language score le 1 ( apply US ) Asymptomatic ( symptomatic define evidence neurological involvement attribute CLN2 disease irrespective CLN2 score , include clinical sign symptom disease seizure , ataxia , language delay developmental delay ) ( apply US )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>